Evidence map›Paper›PMID 36070047›Full record

ArticleMetabolic brain disease2022

Network pharmacological investigation into the mechanism of Kaixinsan powder for the treatment of depression.

Li-Jing Du, Xin-Ning Zhang, Sha-Sha Li, Yuan-Fang Sun, Hui-Zi Jin, Shi-Kai Yan, Chuan-Gang Han

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Mechanisms of Baishao () and Gancao () on major depressive disorder: network pharmacology and o validation.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Li-Jing Du *Department of Anesthesiology, the First People's Hospital of Jiangxia District, Wuhan, China.
Xin-Ning Zhang *The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Sha-Sha LiThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuan-Fang SunThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Hui-Zi JinSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Shi-Kai YanSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China. shkyan@sjtu.edu.cn.
Chuan-Gang HanDepartment of Anesthesiology, the First People's Hospital of Jiangxia District, Wuhan, China. 34826551@qq.com.
Shanghai Jiao Tong University · CNGuangzhou University of Chinese Medicine · CNThe First People's Hospital of Jiangxia District · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaixinsan powder (KXS), a classic prescription of traditional Chinese Medicine (TCM), is widely used in the treatment of depression, but its mechanism remains unclear. The network pharmacology method was used to constructe the "herb-component-target" network, and elucidated KXS potential mechanisms of action in the treatment of depression. Moreover, molecular docking was applied to valid the important interactions between the ingredients and the target protein. The "herb-component-target" network indicated that the ingredients of Girinimbin, Gomisin B and Asarone, and the protein targets of ESR, AR and NR3C1 mostly contribute to the antidepressant effect of KXS. KEGG pathway analysis highlighted the most significant pathways associated with depression treatment, including neuroactive ligand-receptor interaction pathway, serotonergic synapse pathway, PI3K-Akt signaling pathway and MAPK signaling pathway. Go enrichment analysis indicated that the mechanism of KXS in treating depression was involved in the biological process of GPCR signal transduction, hormone metabolism and nerve cell apoptosis. Moreover, molecular docking results showed that Polygalaxanthone III, Girinimbine and Pachymic acid performed greater binding ability with key antidepressant target 5-HTR. In conclusion, this study preliminarily revealed key active components in KXS, including Gomisin B, Asarone, Ginsenoside Rg1, Polygalaxanthone III and Pachymic acid, could interact with multiple targets (5-HTR, DR, ADRA, AR, ESR, NR3C1) and modulate the activation of multiple pathways (Neuroactive ligand -receptor interaction pathway, serotonergic synapse pathway, PI3K-Akt signaling pathway and MAPK signaling pathway).

Indexed as

DepressionPhosphatidylinositol 3-KinasesAllylbenzene DerivativesAnisolesAntidepressive AgentsCyclooctanesDioxolesDrugs, Chinese HerbalLigandsLignansMolecular Docking SimulationPolycyclic CompoundsPowdersProto-Oncogene Proteins c-aktTriterpenesAllylbenzene DerivativesAnisolesAntidepressive AgentsasaroneCyclooctanesDioxolesDrugs, Chinese HerbalKai-Xin-SanLigandsLignanspachymic acidPhosphatidylinositol 3-KinasesPolycyclic CompoundsPowdersProto-Oncogene Proteins c-aktschisantherin BTriterpenesDepressionKaixinsan powderMolecular dockingNetwork pharmacologyTCM

Identifiers

PMID36070047
OpenAlexW4294921987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.